INTRODUCTION
Short bowel syndrome (SBS) is the most common cause of intestinal failure in the pediatric population 1 . Intestinal failure refers to the state of the intestine in which its inadequate surface area renders it incapable of meeting the body's needs in terms of nutrient absorption, hydroelectrolytic equilibrium and motility. These shortcomings result in the intestine's inability to promote growth, requiring parenteral nutrition (PN) in order to meet the nutritional requirements for somatic growth. Consequently, dehydration, electrolyte imbalances and failure to thrive install 2, 3 . The term "short bowel syndrome" is reserved for describing a clinical entity resulting in intestinal failure secondary to extensive intestinal resection 3 . Short bowel syndrome can be defined from several perspectives. Anatomically, SBS is consistent with residual intestinal length less than one-quarter of that predicted for gestational age. Functionally, SBS is defined as the spectrum of malabsorption features occurring after extensive surgical resection 4 . Another functional definition of SBS commonly applied is PN-dependence for a period longer than three months 5 . The etiology of SBS is divided into congenital and acquired; wherein the vast majority of cases are acquired, secondary to surgical resection 2 . Necrotizing enterocolitis (NEC) is the leading cause of intestinal resection leading to SBS in children 6 . Necrotizing enterocolitis accounts for up to 8% of all neonatal intensive care unit (NICU) admissions, in contrast to the range of 0.5 to 2 % in the case of SBS 7 . Congenital SBS is an exceedingly rare entity. Its incidence is estimated at 3-5 cases per 100,000 live births 8 . Preterm birth is a wellestablished risk factor of SBS. The incidence of SBS in preterm neonates is estimated at 353.7/100,000 live births compared to 3.5/100,000 live births in term neonates 9 . Short bowel syndrome is associated with significant morbidity and mortality, carrying a mortality rate of as high as 37.5 percent during the neonatal period 10 .
Various treatment options are available for SBS including medical and surgical counterparts. Medical treatment comprises parenteral nutrition, hormonal agents and hormonal therapy, however parenteral nutrition is the mainstay of therapy 11 . Surgical treatment encompasses two surgical procedures termed Longitudinal Intestinal Lengthening and Tailoring procedure (LILT) and Serial Transverse Enteroplasty Procedure (STEP) and transplantation which may be an isolated intestinal transplant or a combined intestinal-liver transplant 10, 12 . Future therapy comprises a novel surgical technique called Spiral Intestinal Lengthening and Tailoring technique (SILT) 13 , gene therapy targeting the CLMP protein on chromosome 11 14 and tissue regeneration 15 . In this review we discuss the current and future treatment options for SBS.
Secondary Manifestations of Short Bowel Syndrome

Intestinal Failure-Associated Liver Disease
Intestinal Failure-Associated Liver Disease (IFALD), along with CABSI are major causes of morbidity and mortality in SBS. This entity is the most consistent predictor of unfavorable outcome, occurring in as many as 60% of children with SBS 16 20 . Any suspicion of CABSI warrants a thorough assessment, including two blood cultures, and the patient must be started on 48 hour empiric antibiotic treatment as early as a CABSI is suspected. The indications for catheter removal encompass positive cultures on three consecutive days, evidence of fungus growth on culture and signs of hemodynamic instability 21 . A promising new therapy employed in the prevention of CABSI is ethanol lock. Ethanol has been shown to penetrate the biofilms that form on central lines. In addition, no currently know bacterium or fungus is resistant to ethanol. Widely successful, this new therapy has managed to decrease the rate of CABSI, almost five-fold, from 9.9 to 2.2 cases per 1000 catheter days 22 .
Bacterial Overgrowth
Bacterial overgrowth can occur in up to 60% of children with SBS 23 . Bacterial propagation is facilitated by dilated intestinal segments, containing Gram negative microorganisms, the most frequent culprits 24, 25 . The classic complication of bacterial overgrowth is D-lactic acidosis, an anion gap-type acidosis, having the propensity to deteriorate into coma 23 . Laboratory diagnosis is confirmed by serum D-lactate assay. Treatment consists of aggressive rehydration and antibiotics targeting Gram negative anaerobes 26 . Probiotics are not indicated as supportive therapy to antibiotics in the case of bacterial overgrowth in SBS due to evidence that patients developed catheter-associated bloodstream infections 27 .
Intestinal Adaptation
Intestinal adaptation refers to a compensatory mechanism in which the intestine undergoes a course of remodeling. This process may begin as early as 24-48 after birth 28 . Among the changes that occur are mucosal hypertrophy, villous hyperplasia, crypt lengthening, thickening of the muscularis propria layer, all of which ultimately result in dilation of intestinal segments. Intestinal dilation causes dysmotility, which in turn promotes stasis, resulting in bacterial overgrowth 29 . Furthermore, the effects of bacterial overgrowth may prove to be detrimental if bacterial translocation occurs, prompting systemic infection and subsequent sepsis 26 . 30 Nonetheless, prompt transition to enteral nutrition is the desired outcome, as it eludes the risk of developing IFALD as well as catheter-associated bloodstream infections (CABSI). Although PN is a life-saving therapy in neonates with intestinal failure, it is also responsible for inducing numerous long-term complications. The most frequent complication being cholestasis, which may ultimately evolve into IFALD, requiring a combined liver-intestine transplant. Other complications include: CABSI which may lead to sepsis, bacterial overgrowth, azotemia and thromboembolic events. However, the three most common complications are IFALD, CABSI and bacterial overgrowth 31 .
Current Treatment
Supportive Treatment: Parenteral Nutrition
Prokinetic agents
Intestinal dysmotility reflects a central feature of morbidity associated with SBS. Symptoms include difficulty progressing enteral feed, vomiting and abdominal distention 32 . An article published in 2009 in the journal "Neonatology" reviewed all the randomized controlled trials performed to date on oral erythromycin administered in intermediate to high doses in preterm neonates with SBS. Findings included that erythromycin administration was associated with a 50% reduction rate in the incidence of PN-associated cholestasis as well as an equal decrease in the frequency of recurrent septicemia. Although no severe side effects were noted, long-term follow-up was the constraint of this study. Further studies are needed to evaluate the long-term outcomes 33 . The use of metoclopramide and domperidone is controversial due the potential of serious side effects. Metoclopramide induces tardive dyskinesia in up to 30% of patients 32 , while domperidone is known for inducing cardiac dysrhythmia 20 .
Hormonal Agents
The goal of hormonal therapy is to incite intestinal adaptation. Currently, the most promising agent available is Glucagon-like peptide 2 (GLP-2). Administration of Teduglutide has also escalated intestinal adaption, hence improving intestinal function in patients SBS 34 . Additionally, GLP-2 analogues promote villus growth 35 .
Surgical Treatment
The surgical treatment options currently available include bowel conservation, autologous intestinal reconstruction surgery (AIRS) and intestinal transplantation 12 .
Autologous intestinal reconstruction surgery, in turn, consists of two procedures: longitudinal intestinal lengthening and tailoring (LILT) and serial transverse enteroplasty (STEP) 10 . The aims of surgical intervention are to enhance intestinal adaptation, augment the chances of achieving enteral autonomy, and to improve quality of life for both patients and their parents 15 .
Bowel Conservation
Bowel conservation refers to the surgical procedure performed at the first hospital admission. As the name suggests, the goal of this operation is to limit the amount of intestinal resection as much as possible, limited to excision of necrotic intestinal tissue only. In cases where bowel viability is questioned, a "second look" operation may be performed within 24 hours. Secondary closure is used when there is a risk of abdominal compartment syndrome, caused by edematous bowel. Only after edema has subsided, is abdominal wall closure feasible. In the case that bowel continuity cannot be established at the time of bowel conservation surgery, a stoma is placed. The standard time interval between the initial procedure and reestablishing bowel continuity is six weeks 20 .
Longitudinal Lengthening and Intestinal Tailoring Procedure
The longitudinal lengthening and intestinal tailoring operation (LILT) is a type of autologous intestinal reconstruction surgery first introduced by Bianchi in 1980. Essentially, the technique of this procedure is to split the intestine into two longitudinal halves, which are then longitudinally anastomosed to the rest of the patient's intestine. This procedure achieves total mucosal preservation, however fails to increase the total absorptive surface area. Another disadvantage of this procedure is that it must be preceded by bowel dilatation 36 . The surgical outcome was a 28-100% decrease in PN dependence. However, LILT, also known as the Bianchi procedure, is a technically complex procedure; complications such as anastomotic leakage, fistula formation and anastomotic stricture are not uncommon, emphasizing the need for improved surgical techniques 37 . 38 . Additional advantages include shorter operative time due to reduced technical complexity and a shorter learning curve. The most common complication encountered is anastomotic leakage, culminating in peritonitis and staple loosening, resulting in intestinal perforation. In order to avoid these potentiallydeleterious events, reinforcing sutures are placed at the apex of each staple 22 . A retrospective singlecenter study compared the LILT and STEP procedures performed over the course of twentyfour years. Their most prominent findings concern the possibility to wean from PN and its weaning rate. The results acquired after the STEP procedure were superior in both categories. A higher weaning rate in STEP patients was achieved, namely 60% compared to 55% after LILT, and the time required to wean off PN, 4.8 months after the STEP procedure compared to 8.4 months after the Bianchi procedure. However, no differences in patient survival were noted 39 . Another compelling result obtained after the STEP procedure was an increase in postprandial Glucagon-like peptide 2 (GLP-2) levels and increased GLP-2 expression in rats, in a 2009 experiment conducted by Kaji et al. 40 . These results were further reinforced by an analysis of the United States data registry took on by Modi et al., which demonstrated that the STEP procedure had been performed safely and successfully in many centers around the world, with uneventful postoperative recovery 41 .
Serial Transverse Enteroplasty Procedure
Transplantation
Types of intestinal transplantation include isolated intestine, liver-intestine and multivisceral 42 . The first successful combined liver-intestine transplant carried out on a patient with SBS was performed in 1990 43 . Transplantation is reserved as the treatment of last resort. Patients are referred for a transplant in the following conditions: failure of intestinal rehabilitation, no chance of weaning off PN, development of irreversible IFALD, conditions of recurrent sepsis or when central venous access sites have been exhausted 44 . The main complications occurring after transplantation comprise: rejection, graft versus host disease (GVHD), infection and post-transplant lymphoproliferative disease. The five-year survival rate of liver-intestine transplant is 81% compared to 56% after isolated intestinal transplant, as recorded by the Transplant Center at the University of Pittsburgh 45 .
Prognostic Factors
Residual small intestine length is the primary prognostic factor used for assessing parenteral nutrition (PN) dependence. The inflection point above which weaning from PN may be achieved is 35 cm of small intestine 11 . A secondary prognostic factor selected for predicting PN independence is the presence of an ileocecal valve, since it is a marker for remaining ileum 23 . A third method of assessing the ability to wean from PN is measuring the serum citrulline concentration. There is a directly proportional relationship between the serum citrulline concentration and the ability to wean from PN. The cut-off value of serum citrulline under which weaning from PN is not feasible is a value less than 12 mmol/L 24 .
Proposed and Future Therapeutic Strategies
Spiral Intestinal Lengthening and Tailoring Procedure
The newest proposed surgical procedure employed on SBS patients is the Spiral Intestinal Lengthening and Tailoring technique (SILT) proposed by Cserni in 2013. Spiral incision lines are drawn with a marking pen at an angle between 45 to 60 degrees to the longitudinal axis of each intestinal loop. The intestine is then incised on one side, the bowel is rotated and flipped over, and the incision is completed on the opposite side. Next, the bowel is stretched longitudinally over a transluminal catheter into a longer, narrower tube. This technique is advocated to be feasible as less manipulation of the mesentery is required and it does not alter the orientation of muscle fibers, as in the STEP procedure. However, manipulation of the vasa recta is dangerous and may lead to vascular injury, threatening intestinal viability 13 . Thus far, this technique has only been performed on animal models.
Gene-Targeted Therapy
The heritable basis of congenital SBS was first described by Hamilton et al. in 1969 46 , however the underlying genetic mechanism has not be elucidated until 2012 by Van der Welf et al. After performing homozygous mapping using 610,000 K singlenucleotide polymorphism arrays to analyze the genomes of five patients with congenital SBS, Van der Welf identified a mutation in the Coxsackie-and adenovirus receptor-like membrane protein (CLMP) 14 . The genetic basis of congenital SBS is that of an autosomal recessive pattern 47 . CLMP is a transmembrane protein encoded on chromosome 11 that acts as a cohesive molecule at gap junctions between enterocytes. It is hypothesized that a loss of cohesiveness between enterocytes is associated with decreased enterocyte proliferation 12, 14, 48 . Gene-targeted therapy represents a promising therapeutic option for congenital SBS. Furthermore, targeting the mutation in the CLMP protein on chromosome 11 will not only improve the disease prognosis, but also has potential for prenatal diagnosis in addition to genetic counseling 14 .
Tissue Regeneration
The future of SBS therapy may lie in an artificially grown and harvested intestine 15 . Tissue bioengineering techniques first aroused researchers' interest in the 1988 when Vacanti et al. performed a pioneering study describing a method in which cell preparations are attached to biodegradable artificial polymers in organ culture, forming a scaffold, which is then implanted into animals 49 . Choi et al. demonstrated that tissue-engineered small intestine (TESI) is a feasible treatment option for SBS by implanting intestinal epithelial cells seeded on a polyglycolic acid matrix into rats that had undergone resection of 85% of their native intestine. The animals improved in weight gain, while histopathological analysis of the neointestine showed neomucosa formation complete with both Paneth and goblet cells 50 . Thus far, TESI has yielded promising results in animal models; however no studies have been conducted on humans 51 .
Conclusions
Congenital SBS is a disease with high morbidity and mortality, 10 representing the main cause of intestinal failure in the pediatric population 1 . Mortality in this disease has a bimodal distribution: complications in the early post-operative period or intestinal failure-associated liver disease and catheter-associated bloodstream infections in the long-term 20 . The mainstay of treatment of SBS is parenteral nutrition and intestinal rehabilitation 11 . If intestinal rehabilitation is unsuccessful, the last therapeutic resort is intestinal transplantation 44 . The current treatment options are depicted in Figure 1 . Not only does SBS have potential for lifethreatening complications, but also for financial burden propagated by the need for repeated and prolonged hospitalization 52 . Short bowel syndrome is a debilitating disease, whose management stretches over the course of years. The ultimate therapeutic goal is to achieve enteral autonomy. Although a laborious process, it may be achieved by combining both medical and surgical expertise. The role of psycho-social support in achieving positive outcomes should not be underestimated. Surgical staff dedication and family support are indispensable.
Management of pediatric patients with SBS is a complex, long-term process requiring a specialized multidisciplinary approach 15 . However, with the innovation of surgical techniques such as LILT and STEP, as well as advances in multidisciplinary intestinal rehabilitation centers, long-term survival rates are approaching 90% 5 . Future treatment perspectives include tissue and organ regeneration as well as gene targeting therapy. Gene therapy targeting the mutation in the CLMP protein on chromosome 11 may not only improve the disease prognosis, but also has the potential for prenatal diagnosis in addition to genetic counseling 14 . 
